<DOC>
	<DOC>NCT00308438</DOC>
	<brief_summary>The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.</brief_summary>
	<brief_title>Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008</brief_title>
	<detailed_description>The study is sixteen weeks in duration and there are twelve weeks of once-daily injections into your abdomen or thigh. There are a total of five visits.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must have completed participation in the Pilot Active Crohn's Disease Study. Subjects must continue to meet all inclusion criteria for Pilot Active Crohn's Disease Study with the following exceptions: CDAI score greater than 220 Stool samples not required Creactive protein levels are not an exclusion criterion Subject must continue to meet all exclusion criteria for Pilot Active Crohn's Disease Study with the following exceptions: Participation in a clinical study of an experimental drug or device within 30 days before signing consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Crohn Disease</keyword>
	<keyword>Crohn's Disease</keyword>
</DOC>